Octreotide
Performance & EnduranceLong-acting somatostatin analog for acromegaly, carcinoid syndrome, and neuroendocrine tumors.
Key Benefits
- ✓Treats acromegaly
- ✓Controls carcinoid symptoms
- ✓Reduces tumor hormone secretion
- ✓Manages GI symptoms
- ✓Reduces GH levels
- ✓Controls diarrhea
Dosing Information
Detailed Protocol
Immediate-release given via subcutaneous injection 2-3 times daily. Long-acting depot (LAR) given intramuscularly once monthly. Requires medical supervision.
About Octreotide
Octreotide (Sandostatin) is a synthetic octapeptide that mimics somatostatin with longer duration of action. It inhibits GH, insulin, glucagon, and various GI hormones. FDA-approved for acromegaly, carcinoid syndrome, and VIPomas. Available as immediate or long-acting depot.
Research Notes
FDA-approved in 1988. Extensively used for neuroendocrine conditions. Long-acting formulation improves compliance. Well-established efficacy and safety profile.
Potential Side Effects
- •GI upset common
- •Gallstones
- •Injection site pain
- •Hyperglycemia or hypoglycemia
- •Bradycardia
Always consult with a healthcare professional before starting any peptide therapy.